PATENT CLAIM ANALYSIS

Application Number: 16014231
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "259300"]

Abstract:
Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Claim (Index 1):
A compound of Formula 0: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R 1  is hydrogen or halogen; R 3  is hydrogen, halogen, CN, OH, C 1-3 alkyl, C 2-3 alkenyl, C 3-7 cycloalkyl group, C 1 -C 3 alkanoyl, \u2014(C 0 -C 3 alkyl)C(O)NR 6 R 7 , \u2014(C 2-3 alkenyl)C(O)NR 6 R 7 , \u2014S(O) 1-2 NR 6 R 7 , \u2014NR 8 R 9 , \u2014O\u2014C 1-3 alkyl, a 3-7 membered monocyclic saturated or partially saturated heterocyclic group, a 5-6 membered monocyclic heteroaryl ring, or a 5-6 membered monocyclic aryl ring, wherein any alkyl, alkanoyl, or alkenyl is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkoxy, or C 1-3 haloalkoxy, and wherein any cycloalkyl group, heterocyclic group, heteroaryl ring, or aryl ring is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkyl, or C 1-3 haloalkyl; R 4  is hydrogen, halogen, C 1-3 alkyl, C 2-3 alkenyl, \u2014(C 0 -C 3 alkyl)C(O)R 13  \u2014(C 2-3 alkenyl)C(O)NR 10 R 11 , \u2014S(O) 12 NR 10 R 11 , a 3-7 membered monocyclic saturated or partially saturated heterocyclic group, \u2014C(O)NR 8 R 9 , or \u2014NR 8 R 9 , wherein any alkyl, alkenyl, or heterocyclic group is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkoxy, C 1-3 haloalkoxy, or a 3-7 membered monocyclic saturated or partially saturated heterocyclic group that may be optionally substituted with oxo; R 5  is hydrogen, \u2014CN, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl group, \u2014NR 8 R 9 , \u2014C(O)NR 8 R 9 , \u2014O(C 3-7 cycloalkyl group), \u2014O(C 1-3 alkyl)-3-8 membered cycloalkyl group, \u2014O(C 0-3 alkyl)-3-8 membered saturated or partially saturated heterocyclic group, \u2014O(C 1-3 alkyl)-phenyl, a \u2014O(C 1-3  alkyl)-5-6 membered heteroaryl ring, a 3-11 membered saturated or partially saturated heterocyclic group, or a 5-6 membered monocyclic heteroaryl ring, wherein any alkyl or alkoxy is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkoxy, C 1-3 haloalkoxy, or a 3-11 membered saturated or partially saturated heterocyclic group that may be optionally substituted with (i) \u2014C(O)(C 1-3 alkyl) optionally substituted with halogen or (ii) with C 1-3 alkyl optionally substituted with halogen, and wherein any cycloalkyl group, heterocyclic group, phenyl, or heteroaryl ring is optionally substituted by halogen; oxo; CN; OH; C 1-6 alkoxy; \u2014NR 8 R 9 ; \u2014C(O)(C 1-3 alkyl); \u2014(C 0-3 alkyl)C(O)NR 10 R 11 ; \u2014S(O) 12 NR 8 R 9 ; \u2014OP(O)(OC 1-3 alkyl) 2 ; C 3-10 cycloalkyl group optionally substituted with OH or halogen; a 3-11 membered saturated or partially saturated heterocyclic group optionally substituted with oxo or C 1-3 alkyl; a 5-6 membered monocyclic heteroaryl ring optionally substituted by halogen, oxo, CN, OH, C 1-3 alkyl, or C 1-3 haloalkyl; or C 1-4 alkyl optionally substituted by halogen, oxo, CN, OH, \u2014O\u2014C 1-3  alkyl, \u2014S\u2014C 1-3 alkyl, \u2014SO 2 \u2014C 1-3 alkyl, \u2014NR 8 R 9 , \u2014C(O)NR 8 R 9 , phenyl, C 3-10 cycloalkyl, a 3-11 membered saturated or partially saturated heterocyclic group optionally substituted with oxo or C 1-3  alkyl, or a 5-6 membered monocyclic heteroaryl ring optionally substituted with oxo, halogen, or C 1-3 alkyl; A is a 3-11 membered heterocyclic group optionally substituted by halogen, oxo, CN, OH, C 1-6 alkyl, \u2014(C 0-3 alkyl)-C 3-6 cycloalkyl group, a \u2014(C 0-3 alkyl)-3-11 membered heterocyclic group, \u2014NR 8 R 9 , \u2014NR 12 C(O)R 13 , \u2014NR 12 S(O) 12 R 13 , \u2014C(O)(C 1-3 alkyl), \u2014C(O)NR 10 R 11 , \u2014C(O)OR 13 , \u2014S(O) 1-2 NR 10 R 11 , or \u2014(C 0-3 alkyl)-OP(O)(OC 1-3 alkyl) 2 , wherein any alkyl, cycloalkyl group, or heterocyclic group is independently optionally substituted by halogen; oxo; CN; OR 13 ; C 1-3 haloalkoxy; \u2014C(O)(C 1-3 alkyl); \u2014S\u2014C 1-3 alkyl; or C 1-3 alkyl optionally substituted with OH, halogen, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, or a 3-8 membered heterocyclic group, and wherein when A is a 5-membered nitrogen containing heterocyclic group, the nitrogen atom is substituted; R 6  and R 7  are, independently at each occurrence, hydrogen, C 1-3 alkyl, or C 3-6 cycloalkyl group, wherein any alkyl or cycloalkyl group is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, or C 1-3 haloalkoxy; R 8 , R 9 , R 10  and R 11  are, independently at each occurrence, hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl group, \u2014(C 0-3 alkyl)-phenyl, a 3-11 membered saturated heterocyclic group, a 5-6 membered monocyclic heteroaryl ring, \u2014C(O)R 13 , \u2014C(O)OR 13 , \u2014C(O)NR 6 R 7 , or \u2014S(O) 1-2 R 13 , or R 10  and R 11  are taken together to form a 5-8 membered heterocyclic group, wherein any alkyl, cycloalkyl group, phenyl, heterocyclic group, or heteroaryl ring is independently optionally substituted by halogen, oxo, CN, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, \u2014OR 13 , \u2014NR 6 R 7 , or a 5-6 membered monocyclic heteroaryl ring; R 12  is, independently at each occurrence, hydrogen, C 1-6 alkyl or C 3-6 cycloalkyl group, wherein any alkyl or cycloalkyl group is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, or C 1-3 haloalkoxy; R 13  is, independently at each occurrence, hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl group, or a 3-11 membered saturated heterocyclic group, wherein any alkyl, cycloalkyl group, or heterocyclic group is independently optionally substituted by halogen, oxo, CN, OH, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, \u2014OR 12 , or \u2014NR 6 R 7 ; and R 16  is hydrogen, halogen, CN, or C 1-3 alkyl optionally substituted with \u2014NH 2 , halogen, or CN.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.21739
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15905524', '15305390', '15247429', '15822493', '15305372']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8217243902900522
- 35 USC 102 Novelty (BERT): 0.5488820231497212
- Combined Prediction Score: 0.7944401535760192
- Mean Citation Score: 404.523194
- Max Citation Score: 418.23807
- Similarity Product: 310.02771046807413

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test